Literature DB >> 3129956

Disposition kinetics of propofol during alfentanil anaesthesia.

E Gepts1, K Jonckheer, V Maes, W Sonck, F Camu.   

Abstract

The pharmacokinetics of a constant rate infusion of propofol were studied in 11 patients who received total intravenous anaesthesia for ENT surgery. Alfentanil was administered as an exponentially decreasing infusion using a computer-assisted infusion device with a constant target plasma alfentanil concentration of 300 ng/ml. Propofol was infused at a constant rate of 6 mg/kg/hours. Plasma alfentanil concentrations were determined by gas chromatography and whole blood propofol concentrations by high-performance liquid chromatography in arterial blood samples collected at selected times during and up to 8 hours after infusion. Pharmacokinetic modelling of the blood propofol concentration-time data indicated that a three-compartment open model with central elimination was most appropriate. Derived pharmacokinetic parameters were in agreement with previous studies on the pharmacokinetics of propofol. The plasma alfentanil concentrations in 10 patients significantly exceeded the expected values at any time during the infusion. The population mean bias amounted to 20.2% (SD 12.6). Only three data sets were significantly underestimated after the infusion was stopped (mean bias 11.9% (SD 25.5]. The elimination half-life of alfentanil was approximately 75 minutes (SD 21). We conclude that alfentanil does not interfere with the pharmacokinetic profile of propofol but that propofol induces higher plasma alfentanil concentrations than expected.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129956     DOI: 10.1111/j.1365-2044.1988.tb09060.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

1.  Rapid attainment of steady state plasma drug concentrations within precise limits.

Authors:  B Korman; L S Jennings; J R Rigg
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

2.  Randomized comparison of outcome after propofol-nitrous oxide or enflurane-nitrous oxide anaesthesia in operations of long duration.

Authors:  K Korttila; P L Ostman; E Faure; J L Apfelbaum; M Ekdawi; M F Roizen
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

Review 3.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Total intravenous anaesthesia with propofol, alfentanil, and oxygen-air: three different dosage schemes.

Authors:  L van Leeuwen; W W Zuurmond; L Deen; H J Helmers
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

Review 5.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 6.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 7.  Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.

Authors:  B Fulton; E M Sorkin
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 8.  Pharmacokinetic implications for the clinical use of propofol.

Authors:  J Kanto; E Gepts
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 9.  Strategies to optimise propofol-opioid anaesthesia.

Authors:  Bart-Jan Lichtenbelt; Martijn Mertens; Jaap Vuyk
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.